Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 13

Showing 13 citing articles:

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Tina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101633-101633
Open Access | Times Cited: 81
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Wael R. Sidrak, Sanjay Kalra, Atul Kalhan
Indian Journal of Endocrinology and Metabolism (2024) Vol. 28, Iss. 5, pp. 445-460
Open Access | Times Cited: 5
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
David C. D. Hope, Tricia Tan
Peptides (2023) Vol. 162, pp. 170962-170962
Closed Access | Times Cited: 11
Dual glucagon‐like peptide‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
Rajna Golubić, Jane Kennet, Victoria Parker, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2634-2644
Open Access | Times Cited: 3
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Dimitrios Tsilingiris, Alexander Kokkinos
Metabolism (2023) Vol. 151, pp. 155741-155741
Closed Access | Times Cited: 7
Co-agonist therapeutics come of age for obesity
Tricia Tan
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 2, pp. 66-67
Closed Access | Times Cited: 9
Incretin-based therapy: a new horizon in diabetes management
Malek Zarei, Navideh Sahebi Vaighan, Mohammad Hadi Farjoo, et al.
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 2, pp. 1665-1686
Closed Access | Times Cited: 1
Design of novel therapeutics targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) to aid weight loss
Iona Davies, Tricia Tan
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 6, pp. 659-669
Open Access | Times Cited: 3
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
Elena Jiménez-Martí, Gema Hurtado-Genovés, María Aguilar-Ballester, et al.
Nutrients (2022) Vol. 14, Iss. 18, pp. 3775-3775
Open Access | Times Cited: 2
Page 1

Scroll to top